Always consult product-specific labeling for current recommendations
January 15, 2026: FDA Posts Updates to Mounjaros Drug Warning Label, Strengthening Gastrointestinal Warnings On December 19, 2025, and January 7, 2026, the FDA published updates to Mounjaros drug warning label
Effects The effects of Retatrutide extend far beyond simple glucose regulation
CBO expects the above-noted cost per user to go down as more competitors enter the market (though CBO notes that brand prices may not drop if the drugs get better as manufacturers compete on quality as well as price), more generic alternatives appear, more people use AOMs and for longer periods of time, as well as if beneficiaries who were already on AOMs prior to joining Medicare continued their treatment
No tirzepatide drops or oral semaglutide drops
Those early results have sparked widespread attention on social media, especially among influencers and wellness communities eager for the next semaglutide. But the science, and the approval process, arent finished yet
